Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases
Abstract We have recently described Pz-1, a benzimidazole-based type-2 RET and VEGFR2 inhibitor. Based on a kinome scan, here we show that Pz-1 is also a potent (IC50 < 1 nM) TRKA/B/C inhibitor. Pz-1 potently inhibited proliferation of human cancer cells carrying either RET- or TRKA oncoproteins...
Guardado en:
Autores principales: | Marialuisa Moccia, Donglin Yang, Naga Rajiv Lakkaniga, Brendan Frett, Nicholas McConnell, Lingtian Zhang, Annalisa Brescia, Giorgia Federico, Lingzhi Zhang, Paolo Salerno, Massimo Santoro, Hong-yu Li, Francesca Carlomagno |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/eab71864d5a542ee8748ff9464f7f61c |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Crowdsourced identification of multi-target kinase inhibitors for RET- and TAU- based disease: The Multi-Targeting Drug DREAM Challenge.
por: Zhaoping Xiong, et al.
Publicado: (2021) -
Discovery and preclinical characterization of novel small molecule TRK and ROS1 tyrosine kinase inhibitors for the treatment of cancer and inflammation.
por: Ramesh Narayanan, et al.
Publicado: (2013) -
In-silico genome wide analysis of Mitogen activated protein kinase kinase kinase gene family in C. sinensis.
por: Abhirup Paul, et al.
Publicado: (2021) -
In-silico genome wide analysis of Mitogen activated protein kinase kinase kinase gene family in C. sinensis
por: Abhirup Paul, et al.
Publicado: (2021) -
Ca2+/calmodulin-dependent protein kinase kinase is not involved in hypothalamic AMP-activated protein kinase activation by neuroglucopenia.
por: Junji Kawashima, et al.
Publicado: (2012)